Key result
SARS-CoV-2 infection of adipocytes promotes hepatocyte lipid accumulation via infectious viral release.
Why the study?
Obesity and fatty liver may worsen COVID-19 outcomes, but the mechanism by which adipose tissue infection contributes to liver injury is unclear.
Adipose tissue can serve as a source of infectious SARS-CoV-2 that promotes hepatic steatosis, providing a potential mechanism for worsened COVID-19 outcomes in patients with obesity and fatty liver.
Answers are grounded in this paper and cite their sources.
In vitro adipocyte infection data are hypothesis-generating; clinical relevance in COVID-19 remains unproven.
Introduction Obesity and fatty liver may worsen COVID-19 outcomes, but the mechanism by which adipose tissue infection contributes to liver injury is unclear. We aimed to determine whether SARS-CoV-2 infection of human adipocytes promotes inflammation and hepatic lipid accumulation, and to identify the underlying mechanisms. Methods Mesenchymal stem cell–derived human adipocytes were infected with Wuhan SARS-CoV-2 strain. Cell-surface ACE2 expression was measured in adipocytes. Viral replication and infectious titers were measured, and adipocyte morphology, cytokine/adipokine secretion, and lipid metabolism gene expression were analyzed. Culture supernatants from infected adipocytes were then applied to Huh7.5 hepatocytes to evaluate steatosis and fibrogenic activation. Results SARS-CoV-2 productively infected adipocytes, which express cell-surface ACE2, leading to hypertrophy, increased IL-6 secretion, a higher leptin/adiponectin ratio, and lipid droplet accumulation. The infectious virus was released into the supernatants. However, neutralization with anti-Spike antibodies or UV-C inactivation abolished this effect, indicating that hepatocyte lipid accumulation depended on infectious virus rather than on soluble adipocyte-derived mediators alone. Discussion Adipose tissue can serve as a source of infectious SARS-CoV-2 that promotes hepatic steatosis and fibrogenic activation, suggesting a mechanism by which obesity and fatty liver may worsen COVID-19 outcomes, although the contribution of residual infectious virus versus adipocyte-derived factors cannot be fully distinguished. At present, the data do not support an independent role for adipocyte-derived soluble mediators in this effect. The study is intended as a mechanistic in vitro analysis of adipocyte–hepatocyte crosstalk during SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
López et al. (2026) studied SARS-CoV-2 infection and hepatic steatosis. SARS-CoV-2 infection vs. Uninfected cells or UV-inactivated/neutralized virus was evaluated on Hepatocyte lipid droplet accumulation (p=<0.0001). SARS-CoV-2 productively infected adipocytes, releasing infectious virus that promoted significant lipid droplet accumulation in hepatocytes, which was abolished by viral neutralization or UV inactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: